Glioblastoma (IDH-WT, WHO grade 4) · line 1 · Stupp protocol — Temozolomide concurrent + adjuvant
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-STUPP-TMZ |
| ID | IND-GBM-NEWLY-DIAGNOSED-STUPP |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-GBM |
| Sources | SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Notes
PARTIAL — RT 60 Gy / 30 fractions concurrent with TMZ is the defining feature of Stupp; not modellable per PROPOSAL §17. This Indication captures TMZ chemo backbone. Test entities TEST-MGMT-METHYLATION and TEST-IDH-MUTATION referenced but not yet authored (engine validation will flag).
Used By
Algorithms
ALGO-GBM-NEWLY-DIAGNOSED-1L- ALGO-GBM-NEWLY-DIAGNOSED-1L